Human TNF RII/TNFRSF1B Antibody

Detection of TNF RII/TNFRSF1B in Human Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226, filled histogram) or isotype control antibody (MAB003, open histogram) followed by anti-mouse IgG PE-conjugated secondary antibody (F0101B). View our protocol for Staining Membrane-associated Proteins.

TNF RII/TNFRSF1B in Human PBMCs. TNF RII/TNFRSF1B was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

TNF RII/TNFRSF1B Inhibition of TNF‑ alpha -induced Cytotoxicity and Neutralization by Human TNF RII/TNFRSF1B Antibody. Recombinant Human TNF RII/TNFRSF1B inhibits Recombinant Human TNF-a (210-TA) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of Recombinant Human TNF-a (0.25 ng/mL) activity elicited by Recombinant Human TNF RII/ TNFRSF1B (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TNF RII/ TNFRSF1B Monoclonal Antibody (Catalog # MAB226). The ND₅₀ is typically 0.5-1.5 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL).

Detection of Human TNF RII/TNFRSF1B by Immunohistochemistry Representative immunohistochemical staining for TNFR1 and TNFR2 in the kidneys.(A) Images were captured at 200× (a, b, c, d, i, j, k, l) and 100× (e, f, g, h, m, n, o, p) magnification. Images show the negative controls in the glomeruli (a, i) and tubulointerstitium (e, m) and TNFR1 and TNFR2 immunostaining in the glomeruli (b, j) and tubulointerstitium (f, n) of the normal kidneys, respectively. TNFR1 and TNFR2 immunostaining is shown in the glomeruli (c, k) and tubulointerstitium (g, o) of the kidneys from selected IgAN patients who had levels of serum TNFR2 that ranked in the lowest 10 [low group (LG)]. TNFR1 and TNFR2 immunostaining in the glomeruli (d, l) and tubulointerstitium (h, p) of the kidneys from selected IgAN patients who had levels of serum TNFR2 that ranked in the highest 10 [high group (HG)], respectively, are also shown. (B) Percentage of the TNFR1 and TNFR2-positive area in the kidneys were evaluated. Glomerular and tubulointerstitial TNFR expression was elevated significantly in IgAN patients compared with those in control (Ctrl) subjects. The tubulointerstitial TNFR2-positive area was significantly larger in HG than in LG. However, there was no significant difference in the tubulointerstitial TNFR1 and glomerular TNFR areas between LG and HG. * P < 0.01, **P < 0.001, †P < 0.0001. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0122212), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of TNF RII/TNFRSF1B in U937 cells by Flow Cytometry. U937 cells were stained with Mouse Anti-Human TNF RII/TNFRSF1B Monoclonal Antibody (Catalog # MAB226, filled histogram) or isotype control antibody (Catalog # MAB003, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgM Secondary Antibody (Catalog # F0116). View our protocol for Staining Membrane-associated Proteins.